Skip to content
SFN info

Tangier disease and Small Fiber Neuropathy (SFN)

Introduction to Tangier Disease

Description:

Tangier Disease is a rare inherited disorder characterized by significantly reduced levels of high-density lipoprotein (HDL), often referred to as “good cholesterol,” in the blood. It is caused by mutations in the ABCA1 gene, which is involved in the transfer of cholesterol and phospholipids to HDL in the bloodstream. This leads to the accumulation of cholesterol esters in various tissues, causing symptoms such as enlarged yellow-orange tonsils, peripheral neuropathy, and cardiovascular disease.

Prevalence:

Tangier Disease is extremely rare, with fewer than 100 cases reported worldwide. The exact prevalence is unknown due to the rarity of the disease.

Risk Factors:

The primary risk factor for developing Tangier Disease is having two copies of the mutated ABCA1 gene, one from each parent. This is known as an autosomal recessive inheritance pattern. There are no known environmental risk factors for Tangier Disease.

Prognosis:

The prognosis for individuals with Tangier Disease varies. Some individuals may have a normal lifespan with few complications, while others may experience serious health problems such as premature coronary artery disease. Complications can include peripheral neuropathy, enlarged liver and spleen, and an increased risk of developing atherosclerosis due to the low levels of HDL cholesterol.

Prevention:

There are no known preventive measures for Tangier Disease, as it is a genetic disorder. Genetic counseling may be beneficial for families with a history of the disease to understand the risk of passing the condition to offspring.

Epidemiology:

Tangier Disease has been reported in individuals of various ethnic backgrounds and geographical locations. However, due to the rarity of the disease, there is no clear pattern of prevalence by region, age, or gender. The disease typically manifests in childhood or adolescence, but the onset and severity of symptoms can vary widely among individuals.

Tangier Disease connection to Small Fiber Neuropathy (SFN)

Association:

Tangier Disease (TD) is a rare genetic disorder characterized by a deficiency of high-density lipoprotein (HDL), the “good” cholesterol, in the blood. This condition is caused by mutations in the ABCA1 gene, which is responsible for the transfer of cholesterol and phospholipids to apolipoprotein A-I, a protein that forms HDL.

The association between Tangier Disease and Small Fiber Neuropathy (SFN) is not completely understood, but it is believed that the accumulation of cholesterol in the nerves due to the ABCA1 gene mutation may lead to SFN. The excess cholesterol can damage the small nerve fibers, causing the symptoms of SFN.

Research Updates:

Recent research on the connection between Tangier Disease and SFN is limited, likely due to the rarity of the condition. However, a study published in the Journal of Neurology, Neurosurgery & Psychiatry in 2014 reported a case of a patient with Tangier Disease who developed SFN. The study suggested that the accumulation of cholesterol in the nerves may lead to SFN, but more research is needed to confirm this mechanism.

It’s important to note that research in this area is ongoing, and our understanding of the connection between Tangier Disease and SFN may change as new findings emerge.

Symptoms of Tangier Disease

List of Symptoms:

Tangier disease, a rare inherited disorder that is associated with small fiber neuropathy (SFN), can present with a variety of symptoms. The following are some of the common symptoms:

  • Enlarged Tonsils: One of the most distinctive symptoms of Tangier disease is the presence of enlarged, yellow-orange tonsils.
  • Neuropathy: Patients with Tangier disease often experience neuropathy, including SFN. This can result in symptoms such as numbness, tingling, and pain in the hands and feet.
  • Cardiovascular Disease: Tangier disease can lead to an increased risk of developing premature cardiovascular disease due to the accumulation of cholesterol in the arteries.
  • Eye Abnormalities: Some patients may experience eye abnormalities, such as clouding of the cornea.
  • Hepatosplenomegaly: Enlargement of the liver and spleen is another common symptom of Tangier disease.
  • Peripheral Neuropathy: This is a common symptom associated with Tangier disease, often manifesting as weakness, numbness, and pain, usually in your hands and feet.

Severity:

The severity of symptoms in Tangier disease can vary significantly among affected individuals. Some people may have mild symptoms, while others may experience severe and debilitating symptoms.

  • Mild symptoms might include slight numbness or tingling in the extremities.
  • Moderate symptoms could involve more constant numbness, pain, and weakness, particularly in the hands and feet.
  • Severe symptoms could include significant cardiovascular disease, severe neuropathy, and significant hepatosplenomegaly.

Onset:

The onset of symptoms in Tangier disease can vary, but they typically appear in childhood.

  • Early-stage symptoms often include enlarged, yellow-orange tonsils and mild neuropathy.
  • Late-stage symptoms can include more severe neuropathy, cardiovascular disease, hepatosplenomegaly, and eye abnormalities.

It’s important to note that the progression and severity of symptoms can vary significantly among individuals with Tangier disease.## Diagnosis of Tangier Disease

Diagnosis of Tangier Disease

Methods:

Tangier Disease is a rare genetic disorder that is typically diagnosed based on the following:

  • Clinical Evaluation: This involves a thorough physical examination and a detailed patient and family history. Clinicians look for characteristic findings such as enlarged tonsils with an orange or yellow color, a decrease in peripheral pulses, and neurological symptoms.

  • Laboratory Tests: These include blood tests to measure the levels of high-density lipoprotein (HDL) cholesterol and apolipoprotein A-I. In Tangier Disease, these levels are typically very low or undetectable.

  • Genetic Testing: The disease is caused by mutations in the ABCA1 gene. Confirmatory diagnosis often involves genetic testing to identify these mutations.

  • Biopsy: A biopsy of the tonsils, liver, spleen, lymph nodes, or bone marrow may be performed. Under a microscope, cells from these tissues show characteristic changes in people with Tangier Disease.

Differential Diagnosis:

Several conditions might be mistaken for Tangier Disease, especially in the context of small fiber neuropathy (SFN). These include:

  • Familial amyloid polyneuropathy: This is a genetic disorder that also causes SFN. It is characterized by the buildup of abnormal proteins in the body’s organs and tissues.

  • Fabry disease: This is a genetic disorder that can cause SFN and is characterized by a deficiency of the enzyme alpha-galactosidase A.

  • Diabetes: Diabetes is a common cause of SFN. It can lead to peripheral neuropathy, which can cause similar symptoms to Tangier Disease.

  • Chronic inflammatory demyelinating polyneuropathy (CIDP): This condition causes inflammation of nerve roots and peripheral nerves and can also present with similar symptoms.

Limitations:

There are several limitations and challenges in diagnosing Tangier Disease:

  • Rareness of the disease: Tangier Disease is very rare, which means many physicians may not be familiar with it. This can lead to delays in diagnosis.

  • Overlap of symptoms: Many symptoms of Tangier Disease, such as SFN, can also be seen in other conditions, which can lead to misdiagnosis.

  • Lack of definitive tests: While genetic testing can confirm a diagnosis of Tangier Disease, it is not always readily available or affordable. Moreover, not all mutations in the ABCA1 gene have been identified, so a negative genetic test does not necessarily rule out the disease.

  • Variability of symptoms: The symptoms of Tangier Disease can vary greatly from person to person, even among members of the same family. This can make the disease difficult to diagnose based solely on clinical features.

Treatments for Tangier Disease

Options:

Tangier Disease is a rare genetic disorder that affects the body’s ability to transport cholesterol and certain fats. It is associated with small fiber neuropathy (SFN) in some cases. Currently, there is no specific treatment or cure for Tangier Disease. The management of the disease is symptomatic and supportive.

  • Lifestyle Changes: Patients are often advised to maintain a healthy lifestyle, including a balanced diet and regular exercise. This can help manage the lipid levels in the body.
  • Medication: Some patients may be prescribed medication to help manage symptoms. For example, statins or other cholesterol-lowering drugs may be used to help control lipid levels in the blood.
  • Surgery: In severe cases, where there is a significant buildup of cholesterol in the tonsils or other tissues, surgery may be required to remove the affected tissue.

Effectiveness:

The effectiveness of these treatments varies from patient to patient, depending on the severity of the disease and the individual’s overall health.

  • Lifestyle Changes: These changes can help manage symptoms and improve quality of life, but they do not cure the disease.
  • Medication: The effectiveness of medication also varies. Some patients may find relief from symptoms, while others may not respond to the treatment.
  • Surgery: Surgery can be effective in removing cholesterol buildup, but it does not address the underlying genetic disorder.

Side Effects:

Each treatment option comes with potential side effects or risks.

  • Lifestyle Changes: There are generally few side effects associated with lifestyle changes, although drastic changes in diet or exercise should be done under medical supervision.
  • Medication: Side effects of cholesterol-lowering drugs can include muscle pain, liver damage, increased blood sugar, and neurological side effects like memory loss or confusion.
  • Surgery: As with any surgical procedure, there are risks of infection, bleeding, and reactions to anesthesia.

Recent Advancements:

As of now, there are no recent advancements in the treatment of Tangier Disease. However, research is ongoing and future advancements in gene therapy or other fields may provide new treatment options.